MorphoSys (ETR:MOR) has been assigned a €90.00 ($111.11) price objective by analysts at Oddo Bhf in a note issued to investors on Tuesday, February 20th. The brokerage presently has a “buy” rating on the stock. Oddo Bhf’s price objective indicates a potential upside of 4.71% from the stock’s current price.
A number of other brokerages also recently issued reports on MOR. HSBC set a €64.00 ($79.01) price target on shares of MorphoSys and gave the stock a “sell” rating in a report on Friday, January 19th. JPMorgan Chase & Co. restated a “buy” rating on shares of MorphoSys in a report on Monday, January 15th. Goldman Sachs Group set a €72.00 ($88.89) target price on shares of MorphoSys and gave the company a “neutral” rating in a report on Wednesday, November 8th. Deutsche Bank set a €90.00 ($111.11) target price on shares of MorphoSys and gave the company a “buy” rating in a report on Wednesday, November 8th. Finally, Berenberg Bank set a €85.00 ($104.94) price target on shares of MorphoSys and gave the company a “buy” rating in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of €84.02 ($103.73).
MorphoSys (ETR:MOR) traded down €1.30 ($1.60) during mid-day trading on Tuesday, reaching €85.95 ($106.11). 180,040 shares of the company’s stock were exchanged, compared to its average volume of 151,566. The firm has a market cap of $2,530.00 and a P/E ratio of -35.66. MorphoSys has a 12 month low of €49.63 ($61.27) and a 12 month high of €88.40 ($109.14).
TRADEMARK VIOLATION WARNING: This piece was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://stocknewstimes.com/2018/03/14/morphosys-mor-pt-set-at-90-00-by-oddo-bhf.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.